Rousselot has been awarded a patent from the Brazilian patent office for its specialised gelatin technology, StabiCaps.
This is the third patent the gelatin solution has received in the last two years — with the European Patent Office and the US Patent and Trademark Office granting StabiCaps in 2022 and 2023, respectively.
Through this novel patent approval, the company has strengthened its intellectual property (IP) portfolio on a global scale.
StabiCaps is designed to enhance the stability and release profile of softgel capsules.
It achieves this through the reduction of crosslinking — a common challenge when formulating gelatin-based capsules.
StabiCaps also aims to optimise the release of active compounds, allowing nutraceutical manufacturers to produce highly bioavailable and efficacious supplements.
The global softgel market is projected to grow at 6.3% CAGR during the next four years, so the gelatin solution is well-positioned as a solution in this sector.
Rousselot's Director of Functional Ingredients, Pierre-Albert Thomas, commented: “StabiCaps technology offers significant advantages in stability and efficacy for nutraceutical producers, along with the attractive, natural appeal of gelatin,”
“Securing three major international patents, including this latest one in Brazil, underscores the unique value of our technology. We are excited to see how this recognition will open up new opportunities for dietary supplement producers in the rapidly evolving Brazilian health and wellness market.”
